Avenue Biosciences technology collects data sets on how specific signal peptides impact specific protein targets.
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...
Nick Edwards, PhD, CEO of Potato, has a “burning desire” to speed up scientific discovery. In an interview with GEN, he explained how Potato’s AI “scientist,” named Tater, recently replicated a main ...
Silicon Valley microprocessing giant NVIDIA and pharma powerhouse Eli Lilly announced a five-year, $1 billion partnership to create a “Co-Innovation AI Lab” designed to address key challenges in AI ...
Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.
The integration of flexible manufacturing, process intensification, and sustainability is redefining the global supply chain.
Our results provide mechanistic evidence that immune responses to EBV can directly damage the brain in MS,” said Olivia Thomas, PhD, assistant professor at the Department of Clinical Neuroscience at ...
Charles River Laboratories will pay $60 million for the remaining shares of PathoQuest and $510 million for acquiring K.F.
Researchers say the living sensor display technology may have potential applications beyond human healthcare, in veterinary ...
A novel lentiviral packaging system enables production from a single-plasmid transfection instead of the standard four-plasmid process.
The largest single cell perturbation dataset to-date will be generated and released open source in a new team effort.
Data indicate that the AutoCell platform could pave the way for CGTs for the first time as first-line therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback